SV2A and Alzheimer disease: In our subsequent study of [11C]UCB-J in early AD in a larger cohort, we observed more extensive cortical and subcortical reductions in SV2A binding, most pronounced in the hippocampus and entorhinal cortex and more widespread than reductions in gray matter volume [18].